Evidence map›Paper›PMID 37435405›Full record

ArticleFrontiers in psychiatry2023

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.

Simon Zhornitsky, Henrique N P Oliva, Laura A Jayne, Aza S A Allsop, Alfred P Kaye, Marc N Potenza, Gustavo A Angarita

Open access · goldAbstract readScoping Review
In one paragraph

Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Ascorbic acid enhances antidepressant-like efficacy of esketamine: Hippocampal TARP-γ8-containing AMPA receptors mediate synaptic modulation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  4. From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Simon ZhornitskyDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Henrique N P OlivaDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Laura A JayneDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Aza S A AllsopDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Alfred P KayeDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Marc N PotenzaDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Gustavo A AngaritaDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Yale University · USConnecticut Mental Health Center · USNational Center for PTSD · US

Funding

Radiochemistry CoreP30DA046345 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI MACH, ROBERT H · 2019 to 2023
$9.4M
Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C UCB J PET StudyR01DA052454 · NIDA · YALE UNIVERSITY · PI ANGARITA, GUSTAVO ADOLFO · 2021 to 2025
$3.7M
Imaging Synaptic Density in the Opiate Addicted Brain using 11C UCB J PETR21DA046030 · NIDA · YALE UNIVERSITY · PI ANGARITA, GUSTAVO ADOLFO · 2019 to 2020
$461k
NIDA NIH HHS R01 DA052454NIDA NIH HHS R21 DA046030
6 · The paper itself

Abstract

Background: Ketamine and psychedelics have abuse liability. They can also induce "transformative experiences" where individuals experience enhanced states of awareness. This enhanced awareness can lead to changes in preexisting behavioral patterns which could be beneficial in the treatment of substance use disorders (SUDs). Preclinical and clinical studies suggest that ketamine and psychedelics may alter markers associated with synaptic density, and that these changes may underlie effects such as sensitization, conditioned place preference, drug self-administration, and verbal memory performance. In this scoping review, we examined studies that measured synaptic markers in animals and humans after exposure to ketamine and/or psychedelics. Methods: A systematic search was conducted following PRISMA guidelines, through PubMed, EBSCO, Scopus, and Web of Science, based on a published protocol (Open Science Framework, DOI: 10.17605/OSF.IO/43FQ9). Both Results: Eighty-four studies were included in the final analyses. Seventy-one studies examined synaptic markers following ketamine treatment, nine examined psychedelics, and four examined both. Psychedelics included psilocybin/psilocin, lysergic acid diethylamide, N,N-dimethyltryptamine, 2,5-dimethoxy-4-iodoamphetamine, and ibogaine/noribogaine. Mixed findings regarding synaptic changes in the hippocampus and prefrontal cortex (PFC) have been reported when ketamine was administered in a single dose under basal conditions. Similar mixed findings were seen under basal conditions in studies that used repeated administration of ketamine. However, studies that examined animals during stressful conditions found that a single dose of ketamine counteracted stress-related reductions in synaptic markers in the hippocampus and PFC. Repeated administration of ketamine also counteracted stress effects in the hippocampus. Psychedelics generally increased synaptic markers, but results were more consistently positive for certain agents. Conclusion: Ketamine and psychedelics can increase synaptic markers under certain conditions. Heterogeneous findings may relate to methodological differences, agents administered (or different formulations of the same agent), sex, and type of markers. Future studies could address seemingly mixed results by using meta-analytical approaches or study designs that more fully consider individual differences.

Indexed as

addictiondendritePSD-95SV2Asynapsin-1synaptic densitysynaptophysin-1synaptotagmin-1

Identifiers

PMID37435405
PMCPMC10331617
OpenAlexW4382141215

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.